Latest news with #Veeva
Business Wire
2 days ago
- Business
- Business Wire
Novotech Awarded Veeva Hero Award at 2025 Veeva R&D and Quality Summit
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Quality Summit in Seoul, South Korea. Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Quality Summit in Seoul, South Korea. Share Each year, Veeva recognizes industry-leading companies and organizations driving transformational change and growth as "Veeva Heroes." This year, Novotech was recognized for its early and proactive adoption of Veeva platforms to streamline global clinical trials through strong collaboration across sponsors, CRO, and trial sites accelerating drug development and reinforcing its evolution from a regional leader to a global player. 'This recognition was made possible thanks to the dedication and hard work of our cross-functional internal Veeva team, whose efforts were instrumental in achieving this milestone,' stated Dr. Yooni Kim, Managing Director, Asia-Pacific. 'Their commitment and collaborative spirit exemplify the core values that drive our success.' The strategic collaboration between has significantly contributed to mutual growth in the Korean market, enabling biotech and pharma sponsors to accelerate product development and expedite the delivery of innovative therapies to patients. Novotech remains committed to advancing this partnership fostering innovation and driving excellence in clinical research. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
Yahoo
7 days ago
- Business
- Yahoo
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
Veeva Systems VEEV is entering a pivotal phase as it gradually transitions away from Salesforce's infrastructure, aiming to complete the shift by the end of September 2025. This move marks a significant step toward full platform independence, allowing Veeva to operate entirely on its proprietary Vault architecture. The strategy is designed to give Veeva greater control over product development, performance, and long-term innovation — especially as the company deepens its focus on delivering purpose-built software for the life sciences sector. Early signs are promising, with many clients already reporting smoother integration and more consistent performance on Vault. Veeva's recent performance shows just how central the Vault platform has become to its long-term growth story. Veeva has also been proactive in helping its Commercial Cloud customers prepare for the shift, offering migration roadmaps and hands-on support to ease the transition. While increased investment in R&D and customer onboarding may weigh on margins in the short term, Veeva appears focused on the bigger picture, owning its infrastructure to drive faster innovation and long-term differentiation in a highly specialized market. Peers Update For Salesforce CRM, the conclusion of its infrastructure partnership with Veeva marks a natural evolution as both companies refine their long-term strategies. While Veeva was a high-profile example of Salesforce's presence in life sciences, its shift reflects a broader industry trend toward purpose-built platforms. Salesforce continues to expand its healthcare and life sciences offerings through initiatives like Health Cloud and Data Cloud, aiming to meet the growing demand for tailored solutions. Although adoption varies across segments, Salesforce remains a key player with a broad enterprise footprint and a strong innovation pipeline. IQVIA IQV, a major player in the life sciences technology space, continues to compete through its deep data assets and broad service offerings. While its technology stack is not as tightly integrated as Veeva's, IQVIA's scale and diversified model give it a different kind of competitive edge. As Veeva builds out its post-Salesforce identity, IQVIA remains a key peer to watch — particularly in areas where data services and real-world evidence intersect with software. Veeva Systems' Price Performance, Valuation and Estimates Shares of VEEV have gained 36% in the year-to-date period compared with the industry's growth of 8.2%. Image Source: Zacks Investment Research From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.3, above the industry average. VEEV carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Globe and Mail
24-07-2025
- Business
- Globe and Mail
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
Veeva Systems VEEV is entering a pivotal phase as it gradually transitions away from Salesforce's infrastructure, aiming to complete the shift by the end of September 2025. This move marks a significant step toward full platform independence, allowing Veeva to operate entirely on its proprietary Vault architecture. The strategy is designed to give Veeva greater control over product development, performance, and long-term innovation — especially as the company deepens its focus on delivering purpose-built software for the life sciences sector. Early signs are promising, with many clients already reporting smoother integration and more consistent performance on Vault. Veeva's recent performance shows just how central the Vault platform has become to its long-term growth story. Veeva has also been proactive in helping its Commercial Cloud customers prepare for the shift, offering migration roadmaps and hands-on support to ease the transition. While increased investment in R&D and customer onboarding may weigh on margins in the short term, Veeva appears focused on the bigger picture, owning its infrastructure to drive faster innovation and long-term differentiation in a highly specialized market. Peers Update For Salesforce CRM, the conclusion of its infrastructure partnership with Veeva marks a natural evolution as both companies refine their long-term strategies. While Veeva was a high-profile example of Salesforce's presence in life sciences, its shift reflects a broader industry trend toward purpose-built platforms. Salesforce continues to expand its healthcare and life sciences offerings through initiatives like Health Cloud and Data Cloud, aiming to meet the growing demand for tailored solutions. Although adoption varies across segments, Salesforce remains a key player with a broad enterprise footprint and a strong innovation pipeline. IQVIA IQV, a major player in the life sciences technology space, continues to compete through its deep data assets and broad service offerings. While its technology stack is not as tightly integrated as Veeva's, IQVIA's scale and diversified model give it a different kind of competitive edge. As Veeva builds out its post-Salesforce identity, IQVIA remains a key peer to watch — particularly in areas where data services and real-world evidence intersect with software. Veeva Systems' Price Performance, Valuation and Estimates Shares of VEEV have gained 36% in the year-to-date period compared with the industry 's growth of 8.2%. Image Source: Zacks Investment Research From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.3, above the industry average. VEEV carries a Value Score of D. The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
09-07-2025
- Business
- Globe and Mail
Veeva Expands Market Reach Through Targeted Strategic Partnerships
Veeva Systems VEEV is making smart moves in 2025 by expanding its network of high-impact partnerships, helping the company grow faster and become more deeply embedded in how life sciences firms operate. In June, Veeva teamed up with the Sarah Cannon Research Institute to roll out its Clinical Platform across over 200 oncology research sites—a major endorsement of its technology for streamlining cancer trials. In the same month, Astellas chose Veeva's Vault CRM, including its China-specific version, as its global standard for commercial operations. Earlier, in January, Veeva partnered with Zifo to help pharma companies integrate lab quality data more easily into Veeva LIMS, speeding up system rollouts. On the AI front, EVERSANA joined Veeva's partner program in April to co-develop generative AI tools for content creation and customer engagement. Veeva also advanced its regulatory capabilities this year through partnerships with DNAnexus and Accumulus Synergy, making it easier for pharma companies to manage global filings securely and efficiently. These partnerships are helping Veeva drive faster adoption, deepen customer relationships, and unlock new growth opportunities across clinical research, AI-driven engagement, and regulatory compliance. By teaming up with key players, Veeva is expanding its reach and making its platform more indispensable, strengthening both its competitive edge and long-term revenue potential. Peers Update IQVIA Holdings IQV is strengthening its position by expanding into AI-driven solutions across clinical trials and commercialization. In June 2025, the company launched 'AI agents' designed to streamline everything from patient recruitment to trial coordination. It also partnered with NVIDIA in January 2025 to boost its 'Healthcare-grade AI,' enabling automated workflows and advanced analytics across R&D and real-world data platforms. Oracle ORCL continues to update its life sciences platforms, focusing on automation and cloud-based scalability. In March 2025, Oracle made Argus Safety 25.1 Cloud generally available for new SaaS customers, incorporating enhanced automation and workflow management features for pharmacovigilance and case processing. Earlier, in October 2024, Oracle unveiled its next-generation Electronic Health Record system, built on Oracle Cloud Infrastructure, with AI embedded into care workflows such as documentation and appointment preparation. The company also continues to enhance its Clinical One platform, focusing on unifying trial design, randomization, supply management, and data capture in a single cloud-native environment. Veeva's Price Performance, Valuation and Estimates Shares of VEEV have gained 33.5% in the year-to-date period compared with the industry 's growth of 8.1%. From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.25, above the industry average. VEEV carries a Value Score of D. The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oracle Corporation (ORCL): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Yahoo
09-07-2025
- Business
- Yahoo
Veeva Expands Market Reach Through Targeted Strategic Partnerships
Veeva Systems VEEV is making smart moves in 2025 by expanding its network of high-impact partnerships, helping the company grow faster and become more deeply embedded in how life sciences firms operate. In June, Veeva teamed up with the Sarah Cannon Research Institute to roll out its Clinical Platform across over 200 oncology research sites—a major endorsement of its technology for streamlining cancer trials. In the same month, Astellas chose Veeva's Vault CRM, including its China-specific version, as its global standard for commercial operations. Earlier, in January, Veeva partnered with Zifo to help pharma companies integrate lab quality data more easily into Veeva LIMS, speeding up system rollouts. On the AI front, EVERSANA joined Veeva's partner program in April to co-develop generative AI tools for content creation and customer engagement. Veeva also advanced its regulatory capabilities this year through partnerships with DNAnexus and Accumulus Synergy, making it easier for pharma companies to manage global filings securely and efficiently. These partnerships are helping Veeva drive faster adoption, deepen customer relationships, and unlock new growth opportunities across clinical research, AI-driven engagement, and regulatory compliance. By teaming up with key players, Veeva is expanding its reach and making its platform more indispensable, strengthening both its competitive edge and long-term revenue potential. IQVIA Holdings IQV is strengthening its position by expanding into AI-driven solutions across clinical trials and commercialization. In June 2025, the company launched 'AI agents' designed to streamline everything from patient recruitment to trial coordination. It also partnered with NVIDIA in January 2025 to boost its 'Healthcare-grade AI,' enabling automated workflows and advanced analytics across R&D and real-world data platforms. Oracle ORCL continues to update its life sciences platforms, focusing on automation and cloud-based scalability. In March 2025, Oracle made Argus Safety 25.1 Cloud generally available for new SaaS customers, incorporating enhanced automation and workflow management features for pharmacovigilance and case processing. Earlier, in October 2024, Oracle unveiled its next-generation Electronic Health Record system, built on Oracle Cloud Infrastructure, with AI embedded into care workflows such as documentation and appointment preparation. The company also continues to enhance its Clinical One platform, focusing on unifying trial design, randomization, supply management, and data capture in a single cloud-native environment. Shares of VEEV have gained 33.5% in the year-to-date period compared with the industry's growth of 8.1%. Image Source: Zacks Investment Research From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.25, above the industry average. VEEV carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oracle Corporation (ORCL) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
